Implante Transcatéter Valvular Aórtico (TAVI): Podremos Ampliar las Indicaciones?

23_mangione
José Mangione
2014-08-08

More articles by this author

Hay Lugar Aun Para los Inhibidores GPIIbIIIa?

Pedro Ureña Velásquez2014-08-08FACC FSCAI FACCPDirector Medicina Cardiovascular Asociada   

Thromboprophylaxis with antiplatelet agents in patients with mechanical aortic valves

Raúl García-Rinaldo2014-08-08MD, PhD, FACS Ponce School of Medicine, Ponce, PRMayaguez Medical Center, Mayaguez, PR

Evaluation and Management of Asymptomatic Aortic Stenosis

Augusto Pichard2014-08-08Director Innovation and Structural Heart Disease,  Vice Chair, Medstar Heart Institute, Medstar Washington Hospital Center. Professor of Medicine (Cardiology),Georgetown University Medical School.Washington, DC

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

Igor F. Palacios2014-08-08Director of Interventional CardiologyMassachusetts General HospitalProfessor of MedicineHarvard Medical School

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic presentation. Anticoagulation with warfarin has proven effective in...

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended treatment; however, it carries a high complication...

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...